Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Structural insights into the anti-methicillin-resistant Staphylococcus aureus (MRSA) activity of ceftobiprole.

Lovering AL, Gretes MC, Safadi SS, Danel F, de Castro L, Page MG, Strynadka NC.

J Biol Chem. 2012 Sep 14;287(38):32096-102. doi: 10.1074/jbc.M112.355644. Epub 2012 Jul 19.

2.
3.

New and emerging treatment of Staphylococcus aureus infections in the hospital setting.

Moreillon P.

Clin Microbiol Infect. 2008 Apr;14 Suppl 3:32-41. doi: 10.1111/j.1469-0691.2008.01961.x. Review.

4.

Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.

Zhanel GG, Lam A, Schweizer F, Thomson K, Walkty A, Rubinstein E, Gin AS, Hoban DJ, Noreddin AM, Karlowsky JA.

Am J Clin Dermatol. 2008;9(4):245-54. Review.

PMID:
18572975
5.

Can beta-lactams be re-engineered to beat MRSA?

Livermore DM.

Clin Microbiol Infect. 2006 Apr;12 Suppl 2:11-6. Review.

6.

Ceftobiprole Medocaril: BAL5788, JNJ 30982081, JNJ30982081, RO 65-5788, RO 655788.

[No authors listed]

Drugs R D. 2006;7(5):305-11. Review.

PMID:
16922591
7.
8.

Ceftobiprole medocaril: a new generation beta-lactam.

Del Pozo JL, Patel R.

Drugs Today (Barc). 2008 Nov;44(11):801-25. doi: 10.1358/dot.2008.44.11.1264007. Review.

PMID:
19180259
9.

Ceftobiprole: A novel, broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.

Dauner DG, Nelson RE, Taketa DC.

Am J Health Syst Pharm. 2010 Jun 15;67(12):983-93. doi: 10.2146/ajhp090285. Review.

PMID:
20516468
10.

Ceftobiprole: a new beta-lactam antibiotic.

Stein RA, Goetz RM, Ganea GM.

Int J Clin Pract. 2009 Jun;63(6):930-43. doi: 10.1111/j.1742-1241.2009.02041.x. Review.

PMID:
19490203
11.

Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy.

Bush K, Heep M, Macielag MJ, Noel GJ.

Expert Opin Investig Drugs. 2007 Apr;16(4):419-29. Review.

PMID:
17371191
12.

Ceftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus.

Vidaillac C, Rybak MJ.

Pharmacotherapy. 2009 May;29(5):511-25. doi: 10.1592/phco.29.5.511. Review.

PMID:
19397461
13.

MRSA--the tip of the iceberg.

Appelbaum PC.

Clin Microbiol Infect. 2006 Apr;12 Suppl 2:3-10. Review.

14.

Mechanisms of Methicillin Resistance in Staphylococcus aureus.

Peacock SJ, Paterson GK.

Annu Rev Biochem. 2015;84:577-601. doi: 10.1146/annurev-biochem-060614-034516. Review.

PMID:
26034890
15.

Anti-MRSA beta-lactams in development.

Page MG.

Curr Opin Pharmacol. 2006 Oct;6(5):480-5. Epub 2006 Aug 8. Review.

PMID:
16899405
16.

Ceftobiprole: a new broad spectrum cephalosporin.

El Solh A.

Expert Opin Pharmacother. 2009 Jul;10(10):1675-86. doi: 10.1517/14656560903048967. Review.

PMID:
19527192
17.

Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).

Barbour A, Schmidt S, Rand KH, Derendorf H.

Int J Antimicrob Agents. 2009 Jul;34(1):1-7. doi: 10.1016/j.ijantimicag.2008.12.012. Epub 2009 Mar 3. Review.

PMID:
19261449
18.

Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA.

Garrison MW, Kawamura NM, Wen MM.

Expert Rev Anti Infect Ther. 2012 Oct;10(10):1087-103. doi: 10.1586/eri.12.112. Epub 2012 Nov 21. Review.

PMID:
23167512
19.

Clinical profile of ceftobiprole, a novel beta-lactam antibiotic.

Noel GJ.

Clin Microbiol Infect. 2007 Jun;13 Suppl 2:25-9. Review.

20.

Penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus.

Fishovitz J, Hermoso JA, Chang M, Mobashery S.

IUBMB Life. 2014 Aug;66(8):572-7. doi: 10.1002/iub.1289. Epub 2014 Jul 14. Review.

Supplemental Content

Support Center